E. Aronovich

发表

Excision of Sleeping Beauty transposons: parameters and applications to gene therapy

P. Hackett, Zongbin Cui, Geyi Liu, 2004, The journal of gene medicine.

NMR structural analysis of Sleeping Beauty transposase binding to DNA

D. F. Carlson, P. Hackett, E. Aronovich, 2014, Protein science : a publication of the Protein Society.

Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies.

Steven J. Kass, S. Kass, P. Hackett, 2011, Current gene therapy.

Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection

L. Belur, R. McIvor, P. Hackett, 2007, Nature Protocols.

The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

R. McIvor, P. Hackett, E. Aronovich, 2011, Human molecular genetics.

Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Bryan C. Hall, R. McIvor, P. Hackett, 2017, Human gene therapy.

Molecular diagnosis of mucopolysaccharidosis type II (Hunter syndrome) by automated sequencing and computer-assisted interpretation: toward mutation mapping of the iduronate-2-sulfatase gene.

S. Braun, E. Aronovich, C. Whitley, 1995, American journal of human genetics.

Transgene Expression in Dogs After Liver-Directed Hydrodynamic Delivery of Sleeping Beauty Transposons Using Balloon Catheters.

R. McIvor, P. Hackett, E. Aronovich, 2017, Human gene therapy.

Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

P. Hackett, E. Aronovich, T. Beadnell, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II).

R. Latchaw, R. McIvor, B. Blazar, 1996, Human gene therapy.

Molecular Genetic Defect Underlying a-L-lduronidase Pseudodeficiency

E. Aronovich, C. Whitley, D. Pan, 2007 .

Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency.

E. Aronovich, C. Whitley, D. Pan, 1996, American journal of human genetics.

Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.

S. Braun, R. McIvor, R. Anderson, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system.

J. Parker, S. Khan, L. Belur, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Retroviral vector design studies toward hematopoietic stem cell gene therapy for mucopolysaccharidosis type I

R. McIvor, E. Aronovich, C. Whitley, 2000, Gene Therapy.

Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidoses

L. Belur, R. McIvor, P. Hackett, 2007, The journal of gene medicine.

Diagnosis and prevention of lysosomal storage diseases in Russia

M. I. Kuznetsov, E. Aronovich, V. Kozlova, 1993, Journal of Inherited Metabolic Disease.

Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier.

P. Hackett, E. Aronovich, 2015, Molecular genetics and metabolism.

Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II).

S. Braun, R. McIvor, E. Aronovich, 1996, Human gene therapy.

Quantitative Analysis of α-L-Iduronidase Expression in Immunocompetent Mice Treated with the Sleeping Beauty Transposon System

Bryan C. Hall, R. McIvor, P. Hackett, 2013, PloS one.

Caveat to genotype–phenotype correlation in mucopolysaccharidosis type II: Discordant clinical severity of R468W and R468Q mutations of the iduronate‐2‐sulfatase gene

R. Anderson, E. Aronovich, C. Whitley, 1993, Human mutation.

Genotype-phenotype correspondence in Sanfilippo syndrome type B.

E. Aronovich, C. Whitley, H. Zhao, 1998, American journal of human genetics.

Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

W. Low, R. McIvor, E. Aronovich, 2012, Molecular genetics and metabolism.

Molecular basis of mucopolysaccharidosis type IIIB in emu (Dromaius novaehollandiae): an avian model of Sanfilippo syndrome type B.

U. Giger, Ping Wang, E. Aronovich, 2001, Genomics.

Canine heparan sulfate sulfamidase and the molecular pathology underlying Sanfilippo syndrome type A in Dachshunds.

H. Morizono, G. Hoganson, E. Aronovich, 2000, Genomics.

373. Expression of Human Iduronidase from Sleeping Beauty Engineered Human B Lymphocytes as a Cellular Therapy for Mucopolysaccharidosis Type I

R. McIvor, P. Hackett, E. Aronovich, 2015 .

Rational design for enhanced gene therapy with DNA transposons.

P. Hackett, E. Aronovich, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Sleeping Beauty‐mediated correction of Fanconi anemia type C

J. Tolar, K. Clark, P. Hackett, 2011, The journal of gene medicine.

Sleeping Beauty‐mediated correction of Fanconi anemia type C

J. Tolar, K. Clark, P. Hackett, 2011, Journal of Gene Medicine.

The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

R. McIvor, P. Hackett, E. Aronovich, 2011, Human Molecular Genetics.

JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions

D. K. Wood, G. Vercellotti, E. Aronovich, 2023, Journal of thrombosis and haemostasis : JTH.